Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway
Guillaume Robert(Inserm), Patrick Auberger(Inserm)
Cited by 13
Related Papers
Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells
|Oncotarget|2011|119
BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
|Oncotarget|2012|83
Acadesine Kills Chronic Myelogenous Leukemia (CML) Cells through PKC-Dependent Induction of Autophagic Cell Death
|PLoS ONE|2009|80
All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib
|Oncotarget|2012|34
The caspase 6 derived N-terminal fragment of DJ-1 promotes apoptosis via increased ROS production
|Cell Death and Differentiation|2012|20